The Oncology Institute (TOI) Registration Filing summary

Company overview and business model

• Operates a national platform delivering integrated direct care and cost management for cancer and complex conditions, with 121 oncologists and mid-level professionals across 67 clinics in five states.

• Provides community clinics, infusion suites, specialty pharmacy, case management, drug formulary management, and delegated care networks.

• Engages in clinical research in oncology, hematology, and supportive medications and devices.

• Serves Medicare, Medicare Advantage, Medi-Cal, and commercial patients through multiple payor contracts.

Financial performance and metrics

• As of June 5, 2025, 91,913,737 shares of common stock and 202,278 shares of preferred stock are outstanding.

• Net tangible book value as of June 5, 2025, was $(14.9) million, or $(0.16) per share.

• After a $15 million offering at $2.79 per share, net tangible book value would be $(0.66) million, or $(0.01) per share, with immediate dilution of $2.78 per share to new investors.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for general corporate purposes, organic growth, and working capital needs.

• Pending use, proceeds may be invested in short-term, investment-grade, interest-bearing securities.